GlassScriptPhysician profile
Devasis Nolinikant Reddy
NPI 1215457478
$5,085.40
in general payments reported to CMS, 2019-2025
24 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $478 · 2021: $1,166 · 2022: $466 · 2023: $739 · 2024: $716 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $640.90 | 2019-2025 | Tryptyr |
| Biotissue Holdings INC. | $605.90 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $472.98 | 2020-2024 | Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $395.38 | 2019-2021 | |
| New World Medical,INC. | $357.43 | 2023 | |
| Sun Pharmaceutical Industries INC. | $337.00 | 2021-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $292.47 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $285.37 | 2022-2025 | Vyzulta, Xiidra, Envista Mx60 Iol |
| Rxsight INC | $259.83 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Regeneron Healthcare Solutions, INC. | $238.37 | 2019-2021 | |
| Abbvie INC. | $215.00 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $141.83 | 2021 | |
| Shockwave Medical, INC | $129.79 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $124.98 | 2019 | |
| Glaukos Corporation | $115.55 | 2019-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $101.38 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $90.32 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $67.69 | 2023 | Tepezza |
| Allergan, INC. | $59.87 | 2019-2021 | |
| Sight Sciences, INC. | $44.10 | 2023-2024 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $38.20 | 2021 | |
| Oyster Point Pharma, INC. | $25.11 | 2025 | Ryzumvi, Tyrvaya |
| Ivantis, INC | $23.53 | 2020 | |
| Amgen INC. | $22.42 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devasis Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.